Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 10, 2002, Pages 1819-1829

  Gardner, J D ^a   Rodriguez Stanley, S ^b   Robinson, M ^b   Miner Jr , P B ^b  

^a Science for Organizations Inc   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH SALICYLATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; POTASSIUM CHANNEL; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SUCRALFATE;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH EMPTYING; STOMACH PH;

ADULT; CISAPRIDE; CROSS-OVER STUDIES; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTRIC EMPTYING; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; SEROTONIN AGONISTS;

EID: 0036792305     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01342.x     Document Type: Article

References (45)

1. Holloway RH, Bryant W, Dent J. Failure of transient lower oesophageal sphincter relaxation in response to gastric distention in patients with achalasia: Evidence for neural mediation of transient lower oesophageal sphincter relaxations. Gut 1989; 30: 762-7.
2. Holloway RH, Koeyan P, Dent J. Provocation of transient lower esophageal sphincter relaxation by meals with symptomatic gastroesophageal reflux. Dig Dis Sci 1991; 36: 1034-9.
3. Boulant J, Mathieu S, D'Amato M, Abergel A, Dapoigny M, Bommelaer G. Cholecystokinin in transient lower esophageal sphincter relaxation due to gastric distention in humans. Gut 1997; 40: 575-81.
4. A receptors in transient lower esophageal sphincter relaxation triggered by gastric distention. Am J Gastroenterol 1998; 93: 1823-8.
5. Clave P, Gonzalez A, Moreno A, et al. Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. Gastroenterology 1998; 115: 597-604.
6. Hirsch DP, Holloway RH, Tytgat GN, Boeckstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 1998; 115: 1374-80.
7. Zerbib F, Bruley Des Varannes S, Scarpignato C, Leray V, D'Amato M, Roze C. Endogenous cholecystokinin in post-prandial esophageal sphincter function and fundic tone in humans. Am J Physiol 1998; 275: G1266-73.
8. Graham DY, Smith JL, Patterson DT. Why do apparently healthy people use antacid tablets? Am J Gastroenterol 1983; 78: 257-60.
9. Gallup Organization, A Gallup Organization National Survey: Heartburn across America. Princeton, NJ: Gallup Organization, 1988.
10. Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 433-45.
11. Wiseman LR, Faulds D. Cisapride. Drugs 1994; 47: 116-52.
12. Inauen W, Emde C, Weber B, et al. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study. Gut 1993; 34: 1025-31.
13. Galmiche J-P, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-73.
14. Achem SR, Robinson M. A prokinetic approach to treatment of gastroesophageal reflux disease. Dig Dis 1998; 16: 38-46.
15. Washington N, Steele RJC, Jackson SJ, Washington C, Bush D. Patterns of food and acid reflux in patients with low-grade oesophagitis - the role of an anti-reflux agent. Aliment Pharmacol Ther 1998; 12: 53-8.
16. Robinson M. Medical management of gastroesophageal reflux disease. In: Castell DO, Richter JE, eds. The Esophagus, 3rd edn. Philadelphia: Lippincott Williams & Wilkins. 1999: 447-62.
17. + channel KCNQ1 is essential for gastric acid secretion. Gastroenterology 2001; 120: 1363-71.
18. Rampe D, Roy M-L, Dennis A, Brown AM. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417: 28-32.
19. Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 1998; 97: 204-10.
20. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000; 97: 12 329-33.
21. Wysowski DK, Corken A, Gallo-Torres H, Talirico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions. Am J Gastroenterol 2001; 96: 1698-703.
22. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997; 273: H2534-38.
23. Walker BD, Singleton CB, Bursill JA, et al. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol 1999; 128: 444-50.
24. + currents in opossum esophageal circular smooth muscle. Am J Physiol 1999; 277: C1284-90.
25. Robinson M, Rodriguez-Stanley S, Ciociola AA, et al. Synergy between low dose ranitidine and antacid in reducing gastric and esophageal acidity and relieving meal-induced heartburn. Aliment Pharmacol Ther 2001; 15: 1365-74.
26. Gardner JD, Ciociola AA, Robinson M. Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration. J Appl Physiol 2002; 92: 427-34.
27. Gardner JD, Rodriguez-Stanley S, Robinson M, Integrated acidity and the pathophysiology of GERD. Am J Gastroenterol 2001; 96: 1363-70.
28. Grimley CE, Constantinides S, Snell CC, Mills JG, Nwokolo CU. Inhibition of intragastric acidity in healthy subjects dosed with ranitidine 75 mg; a comparative study with cimetidine and placebo. Aliment Pharmacol Ther 1997; 11: 875-9.
29. Ghoos YF, Maes BD, Geypens B, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993; 104: 1640-7.
30. Maes BD, Ghoos YF, Geypens B, et al. Combined carbon-13-glycine/ carbon-14-octanoic acid breath test to monitor gastric emptying rates of liquids and solids. J Nucl Med 1994; 35: 824-31.
31. Maes BD. Ghoos YF, Rutgeerts PJ, Hiele MI. Geypens B, Vantrappen G. [*C]octanoic acid breath test to measure gastric emptying rate of solids. Dig Dis Sci 1994; 39: 104s-106s.
32. Alarcon de la Lasara C, Martin MJ, La Casa MC, Lopez A. Morilva V. Effects of cisapride on ulcer formation and gastric secretion in rats: comparison with ranitidine and omeprazole. Gen Pharm 1996; 27: 1415-20.
33. Voderholzer WA, Klauser AG, Muhldorfer BE, Muller-Lissner SA. Effect of gastric secretory inhibitors and cisapride on gastric volume in healthy volunteers. Eur J Gastroenterol Hepatol 1992; 4: 635-8.
34. 13C breath tests. Dig Dis Sci 1995; 40: 2200-6.
35. 13C] Octanoic acid breath test for gastric emptying of solids: accuracy, reproducibility and comparison with scintigraphy. Gastroenterology 1997; 112: 1155-62.
36. Bell NJV. Burget D. Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
37. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1); 3-7.
38. Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386-406.
39. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in gastroesophageal reflux disease. Gastroenterology 1990; 98: 654-61.
40. Bremner RM, Crookes PF, DeMeester TR, Peters JH, Stein HJ. Concentration of refluxed acid and esophageal mucosal injury. Am J Surg 1992; 164: 522-7.
41. Collen MJ, Johnson DA. Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus. Dig Dis Sci 1992; 37: 570-6.
42. Hirschowitz B. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-58.
43. Hirschowitz B. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci 1996; 41: 1384-91.
44. Hirschowitz B. Gastric secretion of acid and pepsin in patients with esophageal stricture and appropriate controls. Dig Dis Sci 1996; 41: 2115-22.
45. Johansson K-E, Ask P, Boeryd B, Fransson S-G, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986; 21: 837-47.